Collins Amadi, Stephenson D Lawson, Johnbosco Chidozie Okafor, Ezra Agbo
{"title":"Impact of vitamin D and zinc sufficiency on immune responses following COVID-19 vaccinations among healthcare workers.","authors":"Collins Amadi, Stephenson D Lawson, Johnbosco Chidozie Okafor, Ezra Agbo","doi":"10.7774/cevr.2025.14.e17","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vitamin D and zinc sufficiency are theoretically acclaimed to influence immune-boosting potentials following various immunizations. Herein, we explored the impact of these micronutrients on immune responses following Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccination among Nigerians.</p><p><strong>Methods: </strong>Two hundred healthcare workers (HCs) who presented at the Rivers State University Teaching Hospital were recruited during the first dose and followed up 4 weeks post-first and post-second doses. Data (serum vitamin D/zinc, COVID-19 anti-spike immunoglobulin G [ASIgG]) were determined on the day of the first dose and repeated 4 weeks post-first dose and 4 weeks post-second dose. Vitamin D (VitD) status, assessed using serum 25(OH)D, was categorized as sufficient (≥50 nmol/L) or insufficient/deficient (<50 nmol/L) while zinc status was categorized as sufficient (≥11.3 µmol/L) or insufficient (<11.3 µmol/L). Post-second dose ASIgG titer status was categorized as optimal (>7,352 AU/mL) or sub-optimal (<7,352 AU/mL) as defined by the World Health Organization. Statistical significance was defined as p<0.05.</p><p><strong>Results: </strong>HCs with both VitD and zinc sufficiency (n=97) had higher ASIgG titer levels (4 weeks post-first dose=15,977±367.88 AU/mL; 4 weeks post-second dose=22,603±451.18 AU/mL) after the first and second doses compared to only the VitD sufficient (n=58) cohorts (4 weeks post-first dose=4,680±154.77 AU/mL; 4 weeks post-second dose=7,850±200.60 AU/mL) and the zinc-sufficient (n=63) cohorts (4 weeks post-first dose=5,770±160.41 AU/mL; 4 weeks post-second dose=8,100±206.91 AU/mL) (p<0.05). The VitD and zinc-sufficient HCs were also more likely to achieve optimal ASIgG titer levels (odds ratio, 2.97; 95% confidence interval, 2.11-4.123; p<0.001) 4 weeks post-second dose following adjustment for confounders.</p><p><strong>Conclusion: </strong>VitD and zinc sufficiency had a positive impact on immune responses following AstraZeneca COVID-19 vaccination.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 2","pages":"162-168"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046084/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Vitamin D and zinc sufficiency are theoretically acclaimed to influence immune-boosting potentials following various immunizations. Herein, we explored the impact of these micronutrients on immune responses following Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccination among Nigerians.
Methods: Two hundred healthcare workers (HCs) who presented at the Rivers State University Teaching Hospital were recruited during the first dose and followed up 4 weeks post-first and post-second doses. Data (serum vitamin D/zinc, COVID-19 anti-spike immunoglobulin G [ASIgG]) were determined on the day of the first dose and repeated 4 weeks post-first dose and 4 weeks post-second dose. Vitamin D (VitD) status, assessed using serum 25(OH)D, was categorized as sufficient (≥50 nmol/L) or insufficient/deficient (<50 nmol/L) while zinc status was categorized as sufficient (≥11.3 µmol/L) or insufficient (<11.3 µmol/L). Post-second dose ASIgG titer status was categorized as optimal (>7,352 AU/mL) or sub-optimal (<7,352 AU/mL) as defined by the World Health Organization. Statistical significance was defined as p<0.05.
Results: HCs with both VitD and zinc sufficiency (n=97) had higher ASIgG titer levels (4 weeks post-first dose=15,977±367.88 AU/mL; 4 weeks post-second dose=22,603±451.18 AU/mL) after the first and second doses compared to only the VitD sufficient (n=58) cohorts (4 weeks post-first dose=4,680±154.77 AU/mL; 4 weeks post-second dose=7,850±200.60 AU/mL) and the zinc-sufficient (n=63) cohorts (4 weeks post-first dose=5,770±160.41 AU/mL; 4 weeks post-second dose=8,100±206.91 AU/mL) (p<0.05). The VitD and zinc-sufficient HCs were also more likely to achieve optimal ASIgG titer levels (odds ratio, 2.97; 95% confidence interval, 2.11-4.123; p<0.001) 4 weeks post-second dose following adjustment for confounders.
Conclusion: VitD and zinc sufficiency had a positive impact on immune responses following AstraZeneca COVID-19 vaccination.
期刊介绍:
Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide